Challenges with a glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors

Prescriptions of semaglutide, a glucagon-like peptide-1 receptor agonist administered weekly for Type 2 diabetes mellitus and obesity, are increasing. Adverse effects from semaglutide overdose are poorly described. We report adverse effects from three unintentional semaglutide overdoses upon initiation.